全文获取类型
收费全文 | 139390篇 |
免费 | 12388篇 |
国内免费 | 6427篇 |
专业分类
耳鼻咽喉 | 905篇 |
儿科学 | 2382篇 |
妇产科学 | 2065篇 |
基础医学 | 15023篇 |
口腔科学 | 3354篇 |
临床医学 | 14238篇 |
内科学 | 19309篇 |
皮肤病学 | 1794篇 |
神经病学 | 9438篇 |
特种医学 | 3198篇 |
外国民族医学 | 35篇 |
外科学 | 10507篇 |
综合类 | 25294篇 |
现状与发展 | 17篇 |
一般理论 | 1篇 |
预防医学 | 13147篇 |
眼科学 | 3320篇 |
药学 | 15929篇 |
220篇 | |
中国医学 | 8834篇 |
肿瘤学 | 9195篇 |
出版年
2024年 | 489篇 |
2023年 | 1829篇 |
2022年 | 4208篇 |
2021年 | 5419篇 |
2020年 | 4773篇 |
2019年 | 4042篇 |
2018年 | 3957篇 |
2017年 | 4704篇 |
2016年 | 5102篇 |
2015年 | 5085篇 |
2014年 | 9083篇 |
2013年 | 9772篇 |
2012年 | 9313篇 |
2011年 | 10171篇 |
2010年 | 8311篇 |
2009年 | 7457篇 |
2008年 | 7708篇 |
2007年 | 7898篇 |
2006年 | 6845篇 |
2005年 | 6039篇 |
2004年 | 5122篇 |
2003年 | 4358篇 |
2002年 | 3641篇 |
2001年 | 3213篇 |
2000年 | 2672篇 |
1999年 | 2289篇 |
1998年 | 1963篇 |
1997年 | 1690篇 |
1996年 | 1525篇 |
1995年 | 1404篇 |
1994年 | 1186篇 |
1993年 | 979篇 |
1992年 | 882篇 |
1991年 | 699篇 |
1990年 | 625篇 |
1989年 | 522篇 |
1988年 | 437篇 |
1987年 | 363篇 |
1986年 | 334篇 |
1985年 | 460篇 |
1984年 | 340篇 |
1983年 | 215篇 |
1982年 | 304篇 |
1981年 | 170篇 |
1980年 | 177篇 |
1979年 | 110篇 |
1978年 | 83篇 |
1977年 | 63篇 |
1976年 | 59篇 |
1975年 | 36篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Assessment of Myocardial Infarct Size by Three‐Dimensional and Two‐Dimensional Speckle Tracking Echocardiography: A Comparative Study to Single Photon Emission Computed Tomography 下载免费PDF全文
2.
Platelet function has been described by many laboratory assays, and PL-11 is a new point-of-care platelet function analyzer based on platelet count drop method, which counts platelet before and after the addition of agonists in the citrated whole blood samples. The present study sought to compare PL-11 with other three major more established assays, light transmission aggregometry (LTA), VerifyNow? aspirin system and thromboelastography (TEG), for monitoring the short-term aspirin responses in healthy individuals. Ten healthy young men took 100?mg/d aspirin for 3-day treatment. Platelet function was measured via PL-11, LTA, VerifyNow and TEG, respectively. The blood samples were collected at baseline, 2 hour, 1 day during the aspirin treatment and 1 day, 5?±?1 days, 8?±?1 days after the aspirin withdrawal. Moreover, 90 additional healthy subjects were recruited to establish a reference range for PL-11. Platelet function of healthy subjects decreased significantly 2 hours after 100?mg/d aspirin intake and began to recover during 4–6 days after the aspirin withdrawal. Correlations between methods were PL-11 vs. LTA (r?=?0.614, p?<?0.01); PL-11 vs. VerifyNow (r?=?0.829, p?<?0.01); PL-11 vs. TEG (r?=?0.697, p?<?0.001). There was no significant bias between PL-11 and LTA at baseline (bias?=?1.94%, p?=?0.804) using Bland-Altman analysis, while the data of PL-11 were significantly higher than LTA (bias?=?24.02%, p?<?0.001) during the aspirin therapy. The reference range for PL-11 in healthy young individuals was from 66.8 to 90.5% (95%CI). When aspirin low-responsiveness was defined as LTA?>?20%, the cut-off values for each method were, respectively: PL-11?>?50%, VerifyNow?>?533 ARU, TEG?>?60.2%. The results of different platelet function assays were uninterchangeable for monitoring aspirin response and correlations among them were also varied. Correlations among PL-11 and other three major assays suggested the ability of PL-11 to assess the treatment effects of aspirin. But a large cohort study is needed to confirm the cut-off value of aspirin response detected by PL-11. 相似文献
3.
Very preterm children are at increased risk of reduced processing speed at 5 years of age,predicted by typical complications of prematurity and prenatal smoking 下载免费PDF全文
4.
《Vaccine》2019,37(31):4382-4391
Cancer-associated fibroblasts (CAFs), major components of the tumor microenvironment (TME), promote tumor growth and metastasis and inhibit the anti-tumor immune response. We previously constructed a DNA vaccine expressing human FAPα, which is highly expressed by CAFs, to target these cells in the TME, and observed limited anti-tumor effects in the 4T1 breast cancer model. When the treatment time was delayed until tumor nodes formed, the anti-tumor effect of the vaccine completely disappeared. In this study, to improve the safety and efficacy, we constructed a new FAPα-targeted vaccine containing only the extracellular domain of human FAPα with a tissue plasminogen activator signal sequence for enhanced antigen secretion and immunogenicity. The number of CAFs was more effectively reduced by CD8+ T cells induced by the new vaccine. This resulted in decreases in CCL2 and CXCL12 expression, leading to a significant decrease in the ratio of myeloid-derived suppressor cells in the TME. Moreover, when mice were treated after the establishment of tumors, the vaccine could still delay tumor growth. To facilitate the future application of the vaccine in clinical trials, we further optimized the gene codons and reduced the homology between the vaccine and the original sequence, which may be convenient for evaluating the vaccine distribution in the human body. These results indicated that the new FAPα-targeted vaccine expressing an optimized secreted human FAPα induced enhanced anti-tumor activity by reducing the number of FAPα+ CAFs and enhancing the recruitment of effector T cells in the 4T1 tumor model mice. 相似文献
5.
《Journal of pharmaceutical sciences》2019,108(7):2500-2504
Accurately predicting the hepatic clearance of compounds using in vitro to in vivo extrapolation (IVIVE) is crucial within the pharmaceutical industry. However, several groups have recently highlighted the serious error in the process. Although empirical or regression-based scaling factors may be used to mitigate the common underprediction, they provide unsatisfying solutions because the reasoning behind the underlying error has yet to be determined. One previously noted trend was intrinsic clearance-dependent underprediction, highlighting the limitations of current in vitro systems. When applying these generated in vitro intrinsic clearance values during drug development and making first-in-human dose predictions for new chemical entities though, hepatic clearance is the parameter that must be estimated using a model of hepatic disposition, such as the well-stirred model. Here, we examine error across hepatic clearance ranges and find a similar hepatic clearance-dependent trend, with high clearance compounds not predicted to be so, demonstrating another gap in the field. 相似文献
6.
7.
目的探讨补骨脂素抗增生性瘢痕的作用机制。方法体外培养成纤维细胞,按随机数字表法分为正常组(培养正常成纤维细胞)、瘢痕组(培养增生性瘢痕成纤维细胞)、TGF-β1组(10 ng/ml TGF-β1处理增生性瘢痕成纤维细胞5 min^12 h)、Smurf2 RNA干扰组[Smad泛素化调节因子2(Smad ubiquitin regulatory factor2,Smurf2)siRNA转染增生性瘢痕成纤维细胞72 h]、补骨脂素组(10μmol/L补骨脂素处理增生性瘢痕成纤维细胞继续培养72 h)、补骨脂素+TGF-β1组(增生性瘢痕成纤维细胞加入补骨脂素培养72 h后加入TGF-β1培养6 h)。采用Western blot法检测Smurf2、α-平滑肌肌动蛋白(α-actin SMA,α-SMA)蛋白表达;RT-PCR法检测Ⅰ型胶原蛋白mRNA表达;ELISA法检测TGF-β1蛋白分泌。结果与正常组比较,瘢痕组Smurf2蛋白[(0.83±0.08)比(0.38±0.07)]表达增加(P<0.05);与瘢痕组比较,Smurf2 RNA干扰组TGF-β1[(2.2±0.18)比(4.2±0.47)]表达降低(P<0.05);TGF-β1组Smurf2[(0.71±0.06)比(0.42±0.04)]、α-SMA[(1.42±0.12)比(0.91±0.09)]蛋白表达增加(P<0.05),Ⅰ型胶原蛋白mRNA[(0.72±0.09)比(0.41±0.07)]表达增加(P<0.05);补骨脂素组Smurf2[(0.05±0.01)比(0.42±0.04)]、α-SMA[(0.71±0.07)比(0.91±0.09)]蛋白表达降低(P<0.05),Ⅰ型胶原蛋白mRNA表达[(0.12±0.04)比(0.41±0.07)]降低(P<0.05)。结论补骨脂素可能通过TGF-β1/Smurf2信号通路抑制α-SMA蛋白表达,从而降低Ⅰ型胶原蛋白表达,起到抑制瘢痕形成的作用。 相似文献
8.
子宫内膜异位症其异位内膜组织虽然在形态学上呈良性表现,却具有类似恶性肿瘤的生物学特性。中医学一般认为,“正虚伏邪”为恶性肿瘤的病机特点;那么,肾虚血瘀既属于“正虚伏邪”的范畴,又体现了EMs发病学和疾病发生、发展过程中的主要特点。在“病证相应”的中医治则之下,补肾化瘀法的临床疗效主要表现为:缓解痛经症状、提高受孕率,以及调整月经周期。本文基于EMs与恶性肿瘤的相关性,通过分析补肾化瘀法治疗EMs的理论依据及其抑制异位内膜侵袭的调控机制,主要包括解除免疫抑制、阻断局部微血管新生等,旨在阐明其疗效显著的原因,为临床推广提供可靠的基础研究证据。 相似文献
9.
经穹隆结膜入路埋线法重睑成形术应用探讨 总被引:1,自引:0,他引:1
目的:通过分析重睑形成原理,综合比较多种重睑成形的方法,讨论埋线法重睑成形术的优点和可行性。方法:对387例患者行经穹隆结膜入路间断缝合埋线法重睑术。其中88例为其他方法埋线后重睑线消失的患者。结果:手术方法可靠,术后所形成的重睑外形良好,重睑维持时间长。最长随访时间38个月。结论:此方法因符合重睑形成原理,可以充分的将较多的上睑提肌腱膜与上睑皮肤结扎固定、故术后所形成的重睑牢固。且在直视下经穹隆结膜入路,降低了对眼球组织损伤的危险性。是埋线法重睑成形术一种可靠的手术方法。 相似文献
10.